Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma
Go back to Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma| DELCATH SYSTEMS (NASDAQ: DCTH) | Delayed: 16.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.25 | 52 Week High | $4.72 | |||
| Open | $16.47 | 52 Week Low | $0.22 | |||
| Day High | $16.50 | P/E | N/A | |||
| Day Low | $16.12 | EPS | $-102.40 | |||
| Volume | 202 | |||||
